Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 3:45 AM
Ignite Modification Date:
2025-12-25 @ 3:45 AM
NCT ID:
NCT00619502
Brief Summary:
This is a follow-up of Study A3L10 (NCT00315055)
Immunogenicity
* To describe the antibody persistence following a primary series vaccination of either DTaP-IPV-HB-PRP\~T or PENTAXIM™ and ENGERIX B®.
* To describe the immunogenicity of a booster dose of DTaP-IPV-HB-PRP\~T.
Safety
\- To describe the safety profile after a booster dose of DTaP-IPV-HB-PRP\~T.
Study:
NCT00619502
Study Brief:
Protocol Section:
NCT00619502